Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 9, 2024JAMA Network OpenOpen Access

Efficacy and Safety of 5-Day Oral Ensitrelvir for Patients With Mild to Moderate COVID-19

View Full Paper
Ask AI
Bookmark
Share

Authors

HYHiroshi YotsuyanagiNihon UniversityNONorio OhmagariNational Center for Global Health and MedicineYDYohei DoiFujita Health University

Discussion

Loading...

Member takes

Implication

Key Points

Key points are not available for this paper at this time.

Cite This Study

Yotsuyanagi et al. (2024) studied this question.

synapsesocial.com/papers/68e79c4cb6db64358770b76fhttps://doi.org/10.1001/jamanetworkopen.2023.54991
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1A phase 2/3 study of S-217622 in participants with SARS-CoV-2 infection (Phase 3 part)2023 · 48 citations
  2. 2A Randomized Phase 2/3 Study of Ensitrelvir, a Novel Oral SARS-CoV-2 3C-Like Protease Inhibitor, in Japanese Patients with Mild-to-Moderate COVID-19 or Asymptomatic SARS-CoV-2 Infection: Results of the Phase 2a Part2022 · 140 citations
  3. 3Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients2021 · 1,940 citations
  4. 4Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-192022 · 2,241 citations
  5. 51156. Sustained Alleviation and Resolution of Targeted COVID-19 Symptoms with Nirmatrelvir/Ritonavir versus Placebo2022 · 8 citations